Literature DB >> 24104871

Brain metastasis from non-small cell lung cancer (NSCLC): prognostic importance of the number of involved extracranial organs.

L Gerdan1, B Segedin, V Nagy, M T Khoa, N T Trang, S E Schild, D Rades.   

Abstract

BACKGROUND AND
PURPOSE: This study investigated the potential prognostic value of the number of involved extracranial organs in patients with brain metastasis from non-small cell lung cancer (NSCLC).
MATERIAL AND METHODS: A total of 472 patients who received whole-brain radiotherapy (WBRT) alone with 5 × 4 Gy or 10 × 3 Gy for brain metastasis from NSCLC were included in this retrospective study. In addition to the number of involved extracranial organs, 6 further potential prognostic factors were investigated including WBRT regimen, age, gender, Karnofsky Performance Score (KPS), number of brain metastases, and the interval from cancer diagnosis to WBRT. Subgroup analyses were performed for patients with metastatic involvement of one (lung vs. bone vs. other metastasis) and two (lung + bone vs. lung+lymph nodes vs. other combinations) extracranial organs.
RESULTS: The survival rates at 6 months of the patients with involvement of 0, 1, 2, 3, and ≥ 4 extracranial organs were 52, 27, 17, 4, and 14%, respectively (p<0.001). On multivariate analysis, the number of involved extracranial organs remained significant (risk ratio 1.32; 95% confidence interval 1.19-1.46; p<0.001). Age <65 years (p=0.004), KPS ≥ 70 (p<0.001), and only 1-3 brain metastases (p=0.022) were also significantly associated with survival in the multivariate analysis. In the separate analyses of patients with involvement of one and two extracranial organs, survival was not significantly different based on the pattern of extracranial organ involvement.
CONCLUSION: The number of involved extracranial organs is an independent prognostic factor of survival in patients with brain metastasis from NSCLC, irrespective of the pattern of extracranial organ involvement.

Entities:  

Mesh:

Year:  2013        PMID: 24104871     DOI: 10.1007/s00066-013-0439-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  10 in total

1.  Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: stereotactic radiosurgery versus surgical resection.

Authors:  Duong Anh Vuong; Dirk Rades; Albertus T C van Eck; Gerhard A Horstmann; Reinhard Busse
Journal:  Clin Neurol Neurosurg       Date:  2012-06-16       Impact factor: 1.876

Review 2.  Surgical treatment of brain metastasis: a review.

Authors:  Melike Mut
Journal:  Clin Neurol Neurosurg       Date:  2011-11-01       Impact factor: 1.876

3.  Single brain metastasis: resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery.

Authors:  Dirk Rades; Jan-Dirk Kueter; Thekla Meyners; Andre Pluemer; Theo Veninga; Jan Gliemroth; Steven E Schild
Journal:  Clin Neurol Neurosurg       Date:  2011-12-05       Impact factor: 1.876

4.  Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis.

Authors:  D Rades; J D Kueter; J Gliemroth; T Veninga; A Pluemer; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621

5.  Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies.

Authors:  C Nieder; N H Andratschke; H Geinitz; A L Grosu
Journal:  Strahlenther Onkol       Date:  2012-04-26       Impact factor: 3.621

6.  Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis.

Authors:  Dirk Rades; Annika Panzner; Liesa Dziggel; Tiina Haatanen; Radka Lohynska; Steven E Schild
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

7.  Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients.

Authors:  Dirk Rades; Steven E Schild; Radka Lohynska; Theo Veninga; Lukas J A Stalpers; Juergen Dunst
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

Review 8.  Whole-brain radiotherapy in the management of brain metastasis.

Authors:  Deepak Khuntia; Paul Brown; Jing Li; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

9.  Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases.

Authors:  Dirk Rades; Guenther Bohlen; Juergen Dunst; Radka Lohynska; Theo Veninga; Lukas Stalpers; Steven E Schild; Jochen Dahm-Daphi
Journal:  Strahlenther Onkol       Date:  2008-01       Impact factor: 3.621

10.  Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

  10 in total
  14 in total

1.  Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy.

Authors:  Judong Luo; Hong Zhu; Yiting Tang; Honglin Wang; Xifa Zhou; Xujing Lu; Shuyu Zhang; Yunhai Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.

Authors:  Shao-Bo Ke; Hu Qiu; Jia-Mei Chen; Wei Shi; Yong-Shun Chen
Journal:  Curr Med Sci       Date:  2018-12-07

3.  Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.

Authors:  Hatice Odabas; Arife Ulas; Kubra Aydin; Mevlude Inanc; Asude Aksoy; Dogan Yazilitas; Mehmet Turkeli; Sinemis Yuksel; Ali Inal; Ahmet S Ekinci; Alper Sevinc; Nebi S Demirci; Mukremin Uysal; Necati Alkis; Faysal Dane; Mehmet Aliustaoglu; Mahmut Gumus
Journal:  Tumour Biol       Date:  2015-07-07

4.  Lung cancer: Best supportive care - a reasonable option for patients with brain metastases?

Authors:  Dirk Rades; Steven E Schild
Journal:  Nat Rev Clin Oncol       Date:  2016-11-08       Impact factor: 66.675

5.  Predicting brain metastases for non-small cell lung cancer based on magnetic resonance imaging.

Authors:  Gang Yin; Churong Li; Heng Chen; Yangkun Luo; Lucia Clara Orlandini; Pei Wang; Jinyi Lang
Journal:  Clin Exp Metastasis       Date:  2017-01-18       Impact factor: 5.150

6.  Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas.

Authors:  Juliane Rieber; Julian Schmitt; Arne Warth; Thomas Muley; Jutta Kappes; Florian Eichhorn; Hans Hoffmann; Claus Peter Heussel; Thomas Welzel; Jürgen Debus; Michael Thomas; Martin Steins; Stefan Rieken
Journal:  Eur J Med Res       Date:  2015-08-14       Impact factor: 2.175

7.  Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).

Authors:  Qianqian Zhu; Yanan Sun; Yingying Cui; Ke Ye; Chengliang Yang; Daoke Yang; Jie Ma; Xiao Liu; Jinming Yu; Hong Ge
Journal:  Oncotarget       Date:  2017-02-21

8.  External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors.

Authors:  Victor Lewitzki; Rainer J Klement; Sebastian Hess; Rebekka Kosmala; Carsten Nieder; Michael Flentje
Journal:  Clin Transl Radiat Oncol       Date:  2019-02-27

9.  A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.

Authors:  Thiago Pimentel Muniz; Victor Hugo Fonseca de Jesus; Victor Aurélio Ramos Sousa; Malu Viter da Rosa Barbosa; Vladmir Cláudio Cordeiro de Lima
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

10.  Molecular predictors of brain metastasis-related microRNAs in lung adenocarcinoma.

Authors:  Guogui Sun; Xiao Ding; Nan Bi; Zhiwu Wang; Lihong Wu; Wei Zhou; Zitong Zhao; Jingbo Wang; Weimin Zhang; Jing Fan; WenJue Zhang; Xin Dong; Ning Lv; Yongmei Song; Qimin Zhan; LuHua Wang
Journal:  PLoS Genet       Date:  2019-02-01       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.